A question we see often in our Q&A community: "why isn't there a medication for this, like there is for opioids?" It's a fair question, and the honest answer changes what effective treatment actually looks like.
The medication gap
For opioid use disorder, methadone, buprenorphine, and naltrexone are FDA-approved and well-studied. For alcohol use disorder, there are several approved options too. For methamphetamine and cocaine, there is currently no FDA-approved medication that reliably reduces cravings or use the way those do — despite decades of research trying. That's not a reflection of the condition being less serious; stimulant-related overdose deaths have risen sharply, often now involving fentanyl contamination as well. It's a reflection of how differently stimulants act on the brain's reward system, which has made a pharmacological answer much harder to find so far.
What actually works
Because medication isn't the primary lever, stimulant treatment leans more heavily on structured behavioral approaches — and the evidence for a couple of them is genuinely strong:
Contingency management — a structured program where people earn tangible incentives (vouchers, small prizes, or privileges) for verified drug-negative tests — has some of the best evidence of any behavioral intervention for stimulant use disorder specifically. It sounds simple; the research behind it is not.
Cognitive behavioral therapy (CBT) helps identify the specific triggers, thought patterns, and situations that precede stimulant use, and builds concrete alternative responses — this is a mainstay across most quality stimulant treatment programs.
The Matrix Model, developed specifically for stimulant use disorders, combines CBT, family education, individual counseling, 12-step-style support, and drug testing into a structured multi-month outpatient program — one of the more thoroughly studied approaches specific to this category.
What this means when you're choosing a program
If a program's main pitch for stimulant treatment is a medication, that's worth asking follow-up questions about — there isn't a stimulant equivalent of methadone or buprenorphine to prescribe, so the strength of a program here shows up in its behavioral treatment structure, not a prescription pad. Ask specifically whether the program uses contingency management or a structured model like the Matrix Model, and how they handle the co-occurring depression and anxiety that often show up during stimulant withdrawal and early recovery — those symptoms are common and treatable, but need to be part of the plan, not an afterthought.
Our directory lets you filter by level of care and see which centers describe stimulant-specific programming directly on their profile.